Alcobra Ltd. to Present New Data for Metadoxine Extended Release (MDX) at Upcoming Meetings

TEL AVIV, Israel, April 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, will present new data for Metadoxine Extended Release (MDX or MG01CI) at the upcoming 167th Annual Meeting of the American Psychiatric Association (APA) and 69th Annual Scientific Meeting of the Society of Biological Psychiatry (SOBP), both held in New York, NY. Details of the presentations are as follows:

APA Poster Presentation # NR6-21. The effects of ADHD pharmacologic treatments on adult ADHD sub-types with an examination of the effects of MG01CI on adult subjects with PI-ADHD: A presentation of expanded results from the second Phase IIb, randomized, double-blind, placebo-controlled study of metadoxine in adults with Predominantly Inattentive ADHD (PI-ADHD).

Meeting: American Psychiatric Association (APA)
Date / Time: May 5, 2014, 2:30-4:30 PM EDT
Location: Jacob K. Javits Convention Center, 655 W 34th Street, NY
Room: Halls 3A/3B, Level 3

SOBP Poster Presentation # 1364. MG01CI in ADHD and Fragile X Syndrome: A Novel Mechanism of Action: A presentation of key results from a series of preclinical studies designed to further characterize the novel mechanism of action of metadoxine.

Meeting: Society of Biological Psychiatry (SOBP)
Date / time: May 10, 2014, 5:00-6:30 PM EDT
Location: New York Hilton Midtown, 1335 6th Avenue, NY
Room: Americas Hall I, 3rd Floor

About Alcobra Ltd.

Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website,, the content of which is not incorporated herein by reference.

CONTACT: Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 US Investor Contact: LifeSci Advisors, LLC Michael Rice 646-597-6979 Media Enquiries: Sam Brown Inc. Mike Beyer 773-463-4211

Source:Alcobra Ltd.